Sanofi India names Rodolfo Hrosz as new Managing Director
Rodolfo Hrosz will transition from being Sanofi's General Manager, Consumer Healthcare business in Brazil to his new role in India as soon as the applicable regulatory approvals are in place, Sanofi India said in a statement.
Sanofi India Ltd - 500674 - Appointment Of Managing Director
The Board of Directors of the Company at its Meeting held today, based on recommendation of the Nomination and Remuneration Committee approved the appointment of Mr. Rodolfo Hrosz as the Additional Director of the Company with effect from 1st June 2022 and as the Managing Director for a period of three years with effect from 1st June, 2022, subject to approval of the shareholders and other regulatory approvals, as may be required. Mr. Rodolfo Hrosz is not related to any Director of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other Authority. The Press Release in this regard, is enclosed. Please take the above information on record. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are as enclosed: Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 31st March 2022 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Sanofi India Ltd - 500674 - Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 26Th April 2022
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/04/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 26th April 2022; inter alia to consider the unaudited financial results for the quarter ended 31st March 2022 (Q1). Further to our intimation on 28th March 2022, this is to inform you that as per the "Sanofi India Limited- Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the trading window of the Company, which was closed from 1st April 2022, for publication of financial results of the Company for the quarter ended 31st March 2022 shall remain closed up to Thursday, 28th April 2022 (inclusive of both days). Sanofi India Ltd - 500674 - Communication Of Deduction Of Tax At Source On Dividend
Please find enclosed copy of the letter on the above subject sent to the shareholders on 6th April 2022 through email who have registered their email ID with the Company / Depositories. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice of the Annual General Meeting and E-voting information of the Company published on 2nd April 2022, in newspapers, Business Standard and Sakal. Sanofi India Ltd - 500674 - Reg. 34 (1) Annual Report
Dear Sirs Pursuant to Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Report for the financial year ended 31st December 2021 along with the Notice of the 66th Annual General Meeting (AGM) which is scheduled to be held on 26th April 2022 through Video Conferencing (''VC'') facility / Other Audio-Visual Means (''OAVM'') for your information and records. The Annual Report is being sent to the members who have registered their email ID with the Company/Depositories in permitted mode. The members can also access the Annual Report on the website of the Company www.sanofiindialtd.com. For those Members, who have not registered their email address, hard copies of the Notice of the 66th AGM and the Annual Report are being sent at their registered address in the permitted mode. Further details related to AGM are as enclosed. Sanofi India Ltd - 500674 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons we would like to inform you that, inter alia, for the purpose of declaration of financial results of the Company, for the quarter ending 31st March 2022, the trading window of the Company shall remain closed from 1st April 2022 till 48 hours after the announcement of the results to the stock exchanges. Kindly take the above information on record.